Nasdaq:ALDX
Aldeyra Therapeutics, Inc.
A clinical-stage biotech firm pursuing transformative gene therapy candidates for rare neurological and ocular diseases with a strong focus on precision medicine.
Key Metrics
Investment Thesis
Bull Case
Aldeyra offers exposure to high-potential gene therapies for rare diseases with a differentiated technology platform that could yield blockbuster orphan drug revenues upon approval. The company's strategic partnerships and asset sales have successfully replenished cash reserves, reducing immediate liquidity concerns despite current losses. Early clinical data successes in neurological indications could validate the pipeline and attract further capital at valuations below current market prices.
Bear Case
The absence of revenue and a widening accumulated deficit of -$484.0M presents a severe solvency risk if future fundraising efforts fail or dilute existing shareholders excessively. High operating expenses exceeding $35M annually without commercial milestones suggest the company may struggle to reach profitability in the short-to-medium term. Investors face significant binary risks associated with clinical trial failures and lengthy regulatory pathways for complex gene therapies.
About Aldeyra Therapeutics, Inc.
Aldeyra Therapeutics is a clinical-stage biopharmaceutical company focused on developing first-in-class therapies for rare diseases, primarily targeting neurological disorders and retinal conditions. The company operates in the specialized medical device and pharmaceutical markets, leveraging its proprietary technology platform to address unmet needs in orphan drug development.
Analysis
Management Discussion
Despite generating no revenue, Aldeyra maintained a robust cash position of $70.0M at year-end, partially funded by $88.0M in marketable security proceeds and $1.1M in financing cash flows. However, the company reported a net loss of $33.8M in 2025 driven by substantial R&D expenditures of $25.7M and operating expenses of $35.3M, resulting in a retained earnings deficit of -$484.0M.
Industry Overview
The rare disease therapeutics sector is characterized by high R&D costs, substantial regulatory hurdles, and limited competition due to the small patient populations involved. Companies in this space often rely on strategic partnerships to offset development costs, creating a landscape where successful clinical breakthroughs can lead to outsized returns. The market currently favors firms with strong cash reserves capable of funding long clinical trials before generating commercial sales.
Financial Statements
Income Statement
Balance Sheet
Cash Flow
| Metric | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| Cost of Revenue | $0 | $0 | $0 | $0 |
| Gross Profit | $0 | $0 | $0 | $0 |
| Operating Expenses | $62.7M | $42.8M | $60.1M | $35.3M |
| Operating Income | $-62.7M | $-42.8M | $-60.1M | $-35.3M |
| R&D | $47.3M | $29.5M | $48.2M | $25.7M |
| G&A | $15.4M | $13.3M | $11.9M | $9.6M |
| Stock-Based Comp | $8.3M | $5.8M | $8.0M | $6.1M |
| Depreciation | $258.7K | $262.8K | $249.6K | $252.0K |
| Other OpEx | $0 | $0 | $0 | $0 |
| Non-Operating Income | $0 | $0 | $0 | $69.1M |
| Interest Expense | $1.7M | $2.1M | — | — |
| Interest Income | $2.3M | $7.3M | $6.2M | $3.3M |
| Pre-Tax Income | $-62.7M | $-42.8M | $-60.1M | $33.8M |
| Income Tax | $0 | $0 | $1.0K | $0 |
| Continuing Ops | $-62.7M | $-42.8M | $-60.1M | $33.8M |
| Discontinued Ops | $0 | $0 | $0 | $-67.7M |
| Net Income | $-62.0M | $-37.5M | $-55.9M | $-33.8M |
| Minority Interest | $0 | $0 | $0 | $0 |
| Net to Common | $-62.0M | $-37.5M | $-55.9M | $-33.8M |
| Metric | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Current Assets | $181.0M | $147.8M | $104.1M | $71.8M |
| Cash & Equivalents | $144.4M | — | $54.5M | $70.0M |
| Marketable Securities | $29.9M | — | $46.6M | — |
| Prepaid Expenses | $6.7M | $5.0M | $2.9M | $1.7M |
| Other Current Assets | $0 | $142.8M | $0 | $0 |
| Long-Term Assets | $268.5K | $516.6K | $534.2K | $275.9K |
| PP&E (Net) | $19.3K | $5.8K | $0 | — |
| Operating Leases | $249.3K | $510.8K | $267.0K | $275.9K |
| Other LT Assets | $0 | $0 | $267.3K | $0 |
| Total Assets | $181.3M | $148.3M | $104.6M | $72.1M |
| Current Liabilities | $15.4M | $22.3M | $18.6M | $27.8M |
| Accounts Payable | $133.6K | $1.3M | $180.5K | $158.5K |
| Current Debt | $911.8K | $15.1M | $31.4K | $15.2M |
| Current Leases | $249.3K | $239.2K | $271.6K | $280.5K |
| Other Current Liab | $0 | $0 | $6.0M | $6.0M |
| Long-Term Liabilities | $14.9M | $6.3M | $15.0M | $0 |
| Long-Term Debt | $14.9M | $0 | $15.0M | $0 |
| LT Operating Leases | $0 | $271.6K | $0 | $0 |
| Other LT Liab | $-911.8K | $-9.1M | $0 | $0 |
| Total Liabilities | $30.3M | $28.5M | $33.6M | $27.8M |
| Shareholders' Equity | $151.0M | $119.8M | $71.0M | $44.3M |
| Retained Earnings | $-356.7M | $-394.3M | $-450.1M | $-484.0M |
| AOCI | $-103.9K | $0 | $37.4K | $0 |
| Total L&E | $181.3M | $148.3M | $104.6M | $72.1M |
| Metric | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Net Income (CFO) | $-62.0M | $-37.5M | $-55.9M | $-33.8M |
| Non-Cash Adjustments | $1.3M | $15.8M | $10.9M | $8.0M |
| Working Capital Changes | $4.1M | $-8.6M | $1.8M | $-7.5M |
| Cash from Operations | $-56.6M | $-30.3M | $-43.2M | $-33.3M |
| Capital Expenditures | $16.3K | $0 | — | — |
| Cash from Investing | $-30.0M | $30.0M | $-44.9M | $47.7M |
| Cash from Financing | $1.2M | $-1.3M | $-171.4K | $1.1M |
| FX Effect | $0 | $0 | $0 | $0 |
| Net Change in Cash | $-85.4M | $-1.6M | $-88.3M | $15.5M |
| Beginning Cash | $229.8M | $144.4M | $142.8M | $54.5M |
| Ending Cash | $144.4M | $142.8M | $54.5M | $70.0M |
Frequently Asked Questions
How does Aldeyra Therapeutics, Inc. make money?
The company's operations are concentrated in two primary segments: Research & Development, which drives its pipeline of novel therapies for rare diseases, and Strategic Partnerships/Licensing, evidenced by significant non-operating income and cash inflows from external collaborations or asset sales.
What are the main risks for ALDX?
Significant losses totaling $33.8M in 2025 indicate high burn rates typical of pre-revenue biotech firms; Reliance on external funding sources due to lack of current revenue generation; Regulatory approval uncertainties for novel gene therapy candidates; Potential dilution from equity issuances as seen in cash flow financing activities.
What is ALDX's competitive advantage?
First-in-class technology platform enabling unique therapeutic approaches to rare genetic disorders; Strong balance sheet with approximately $70M in cash providing runway for clinical advancement; Specialized expertise in delivering complex therapies to the brain and eye.
Related Companies
Not financial advice. All content is for informational purposes only. Data may contain errors. Consult a qualified financial advisor before making investment decisions.